Our proprietary CDH17 biomarker transforms the landscape of cancer therapeutics, offering precision and effectiveness in targeting gastrointestinal cancers. Committed to advancing medical science, we leverage CDH17 to develop targeted therapies that …

Arbele is driven by a vision to revolutionize cancer treatment through innovative immunotherapy solutions. Our dedicated team of experts is committed to developing antibody-based biologics that target gastrointestinal cancers, including stomach, pancreas, colon, bile duct, and liver.

Oct 10, 2024 · Leveraging the PredictX platform to develop AI-based models using Arbele's clinical trial data on colorectal cancer (CRC) biomarker screening, we join force to establish a gold standard companion diagnostic test for anti-CDH17 therapies for patient selection and prediction of clinical outcomes.

Arbele has developed its proprietary technology mainly on two platforms: next-generation chimeric antigen receptor T (CAR-T) cells and multi-specific T cell engaging antibodies.

Aug 2, 2023 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique differential binding affinities...

Apr 26, 2024 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells.

SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the...

Oct 9, 2024 · Leveraging the PredictX platform to develop AI-based models using Arbele's clinical trial data on colorectal cancer (CRC) biomarker screening, we join force to establish a gold standard...

Aug 2, 2023 · ARB202 is a first-in-class bispecific antibody based on Arbele’s patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique differential binding affinities of ARB202 toward CDH17 and CD3 allows it to have high specificity and cytotoxicity, while avoiding the “off-target” overactivation of T cells.

Apr 26, 2024 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells.